Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

Thursday, October 25, 2012

Positive Data on Sanofi's Aubagio - Analyst Blog

October 24, 2012


Sanofi ( SNY ) and its subsidiary Genzyme recently presented positive data on its oral treatment for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide). The company presented data from the phase III TOWER trial at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

The phase III TOWER trial, conducted on RMS 1,169 patients, evaluated Aubagio in two dosage strengths, 7mg and 14mg. Patients in the 14mg dosage Aubagio arm demonstrated a 36.3% reduction in annualized relapse rate compared to placebo. The reduction was statistically significant. Additionally, a 31.5% reduction in the risk of 12-week sustained accumulation of disability was also observed.

Meanwhile, patients in the 7mg dosage Aubagio arm demonstrated a 22.3% reduction in annualized relapse rate compared to placebo. However, the reduction in the risk of 12-week sustained accumulation of disability was not statistically significant.

On September 12, 2012, the US Food and Drug Administration (FDA) approved Aubagio as a once-daily treatment for patients with RMS. Aubagio is currently under regulatory review in the EU with a final decision expected in the first quarter of 2013.

Competition in the oral multiple sclerosis market is intense. Novartis' ( NVS ) Gilenya already has a lead in the oral MS market with the product being approved in September 2010. Another major competitor could be Biogen Idec's ( BIIB ) BG-12, which is currently under regulatory review in the US and EU.

Our Recommendation

We currently have a Neutral recommendation on Sanofi. We are pleased with the company's efforts to develop its pipeline. We expect Sanofi to continue to contain operating costs in order to increase earnings in the face of weakening sales of some of its biggest products. We also expect the company to pursue bolt-on acquisitions.


Read more: http://community.nasdaq.com/News/2012-10/positive-data-on-sanofis-aubagio-analyst-blog.aspx?storyid=184233#ixzz2AKALJDMx


..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

1 comment:

steve s said...

Big pharma is anxious to enter the oral MS therapy arena for good reason. Aubagio may be good for mild cases of rrms but do clinicians really want to use this compound when other oral agents such as gilenya or soon to be approved BG-12 are available?